mCPP: an undesired addition to the ecstasy market.
Matthijs G. Bossong, Tibor M Brunt, J P Van Dijk, S M Rigter, J Hoek, H M J Goldschmidt, Raymond J.m. Niesink
Journal of Psychopharmacology September 2010 DOI: 10.1177/0269881109102541 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | MDMA |
| Key points | Argues that mCPP is an undesired addition to the ecstasy market because its tablets are indistinguishable from MDMA tablets and user reports of its effects are predominantly negative. |
Abstract
A new ecstasy-like substance, meta-chlorophenylpiperazine (mCPP), has been detected in street drugs in the Netherlands. Theoretically, mCPP possesses the potential to become a non-neurotoxic alternative for methylenedioxymethamphetamine (MDMA), the regular psychoactive substance of ecstasy. Since its introduction on the Dutch market of synthetic drugs, the percentage of mCPP-containing tablets has increased, including both tablets that contain only mCPP and tablets containing a combination of mCPP and MDMA. These tablets occur in many different colours, shapes and sizes and with various logos, making it impossible to distinguish mCPP-containing tablets from regular MDMA tablets. In addition, the reports of users concerning the effects of mCPP are predominantly negative. All these aspects together lead to the conclusion that mCPP is an undesired addition to the ecstasy market from the user's perspective.
Citations in the library
Cited by 19
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Instability of the ecstasy market and a new kid on the block: mephedrone Journal of Psychopharmacology September 8, 2010
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Testing and Analysis 2014
- The variability of ecstasy tablets composition in Brazil. Journal of Forensic Sciences 2015
and 14 more in the library
Cites 7
- The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences March 1, 1992
- A review of the acute subjective effects of MDMA/ecstasy Addiction March 24, 2006
- Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction February 27, 2006
- The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA) CNS Drug Reviews June 1, 2004
- Hallucinogens. Pharmacology & Therapeutics February 1, 2004
and 2 more in the library